Table 1. In Vitro Cytotoxic Activity of the Designed Compounds.

	IC50 (μM)a
comp. no	HePG2b	MCF-7c	PC3d	HCT-116e
5-FUf	9.42 ± 0.46	7.75 ± 0.37	10.34 ± 0.50	8.01 ± 0.39
3a	11.64 ± 0.57	60.03 ± 2.93	26.91 ± 1.28	49.92 ± 2.36
3b	12.36 ± 0.59	42.36 ± 2.13	18.36 ± 0.89	30.86 ± 1.52
3c	14.12 ± 0.68	25.38 ± 1.20	25.80 ± 1.30	18.30 ± 0.89
3d	16.21 ± 0.77	19.88 ± 0.96	20.49 ± 0.97	20.02 ± 0.99
3e	11.60 ± 0.57	45.94 ± 2.18	25.87 ± 1.25	50.74 ± 2.50
4a	10.01 ± 0.49	75.68 ± 3.74	35.27 ± 1.67	50.02 ± 2.44
4b	11.95 ± 0.59	19.18 ± 0.94	15.00 ± 0.74	20.19 ± 0.96
4c	8.02 ± 0.38	15.74 ± 0.78	13.64 ± 0.67	7.15 ± 0.35
4d	6.95 ± 0.34	8.50 ± 0.42	14.08 ± 0.70	8.35 ± 0.42
4e	11.50 ± 0.56	55.48 ± 2.71	35.08 ± 1.73	65.09 ± 3.08

^aIC₅₀ (μM): Expressed as mean ± S.D. 1–10 (very strong), 11–20 (strong), 21–50 (moderate), 51–100 (weak), and above 100 (noncytotoxic).

^bHuman hepatocellular carcinoma cell line (HepG2).

^cHuman breast adenocarcinoma cell line (MCF-7).

^dHuman prostate cancer cell line (PC3).

^eHuman colorectal carcinoma cell line (HCT-116).

^f5-FU: 5-fluorouracil.